Key facts
- This page summarizes Herbert J. Conrad's Form 4 filing for Celldex Therapeutics, Inc. (CLDX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2022, 16:08.
Herbert J. Conrad - 16 Jun 2022 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)
- Reporting relationship
- Director
- Issuer ticker
- CLDX
- Reported as of
- 16 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2022, 16:08:27 UTC
- Prior SEC filing
- 02 Nov 2021
- Next SEC filing
- 16 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Samuel B. Martin, attorney-in-fact for Herbert J. Conrad
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Herbert J. Conrad filed Form 4 for Celldex Therapeutics, Inc. (CLDX) on 17 Jun 2022.
Change
- Previous filing in this sequence was filed on 02 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDX
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +13,600
- Change %
- Price
- $0.000000
- Shares after
- 13,600
- Date
- 16 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,600
- Exercise price
- $22.48
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.